In order to evaluate the effect of adding doxorubicin ( A ) and cyclophosphamide ( C ) to tamoxifen ( TAM ) ( ACT ) on the overall survival ( OS ) of node-positive postmenopausal breast cancer ( PMBC ) patients , we conducted a randomized trial .